Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 88 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Nausea With Vomiting Chemotherapy-Induced Clear all
Completed Phase 3 Interventional Results available

Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy

NCT01500213
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Rolapitant, Granisetron, Dexamethasone, Placebo
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 1, 2016 · Synced Sep 17, 2026, 4:09 AM EDT
Terminated Phase 4 Interventional

A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemotherapy-induced Nausea and Vomiting

NCT00418678
View directory record Official record
Conditions
Nausea and Vomiting
Interventions
Cesamet
Drug
Lead sponsor
Veeda Oncology
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 1, 2010 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

Use of Aromatherapy to Reduce Symptom Burden

NCT05251337
View directory record Official record
Conditions
Anxiety, Chemotherapy-induced Nausea and Vomiting
Interventions
Essential oils, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 100 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting

NCT01363479
View directory record Official record
Conditions
Chemotherapy-Induced Nausea and Vomiting
Interventions
Oral palonosetron, I.V. palonosetron, Dexamethasone
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Hot Springs, Arkansas • Corona, California • Fountain Valley, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Sep 17, 2026, 4:09 AM EDT
Terminated Phase 2 Interventional Results available

Low Dose Aprepitant for Patients Receiving Carboplatin

NCT03237611
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Aprepitant 125 mg, Fosaprepitant 115 MG, Dexamethasone, Ondansetron 16 MG
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens

NCT02635984
View directory record Official record
Conditions
Complications of Bone Marrow Transplant, Hematologic Neoplasms
Interventions
Olanzapine, Placebo
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2018 · Synced Sep 17, 2026, 4:09 AM EDT
Withdrawn Phase 3 Interventional

A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy

NCT00891761
View directory record Official record
Conditions
Cancer, Chemotherapy-Induced Nausea and Vomiting, Nausea and Vomiting, Solid Tumor Cancer
Interventions
Dexamethasone, IV casopitant (placebo), IV casopitant (active), Ondansetron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Tampa, Florida • Robbinsdale, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting

NCT00787566
View directory record Official record
Conditions
Chemotherapy-Induced Nausea and Vomiting
Interventions
Intranasal granisetron
Drug
Lead sponsor
Shin Nippon Biomedical Laboratories, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
The Study Is Managed by Kendle International, in Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2011 · Synced Sep 17, 2026, 4:09 AM EDT
Recruiting No phase listed Observational

Evaluating the Association Among Changes in Gut Microbiome, Fatigue, and Chemotherapy-Induced Nausea in Early Stage Breast Cancer

NCT05417867
View directory record Official record
Conditions
Chemotherapy-Related Nausea and/or Vomiting, Early Stage Breast Carcinoma, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Interventions
Biospecimen Collection, Questionnaire Administration
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Terminated Phase 3 Interventional Results available

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

NCT04503668
View directory record Official record
Conditions
Gynecologic Cancer
Interventions
Ondansetron, Dexamethasone, Neurokinin-1 Receptor Antagonist (NK1-RA), Olanzapine, Compazine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults

NCT00437229
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
Casopitant (GW679769) Oral Tablets, dexamethasone, ondansetron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects

NCT00511823
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
casopitant, dolasetron, granisetron, rosiglitazone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Sep 17, 2026, 4:09 AM EDT
Recruiting Phase 3 Interventional

Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan

NCT06588413
View directory record Official record
Conditions
Multiple Myeloma, Autologous Stem Cell Transplantation
Interventions
Olanzapine
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting

NCT03204279
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting (CINV)
Interventions
Netupitant, Palonosetron
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
Up to 17 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Wilmington, Delaware • Jacksonville, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects

NCT02434861
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Rolapitant, Digoxin, Sulfasalazine, Cooperstown Cocktail
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Sep 17, 2026, 4:09 AM EDT
Terminated Phase 4 Interventional Results available

Steroid-sparing Therapy (Olanzapine) Versus Dexamethasone-based Therapy for Chemotherapy-induced Nausea and Vomiting

NCT05590923
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
OLA group: Olanzapine, DEX group: Dexamethasone
Drug
Lead sponsor
The Guthrie Clinic
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Sayre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Withdrawn Phase 2 Interventional

Granisetron Extended Release Injection (GERSC) for the Prevention of Chemotherapy-induced Nausea and Vomiting

NCT04085393
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
GRANISETRON EXTENDED RELEASE INJECTION (GERSC)
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

Olanzapine for Nausea/Vomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants

NCT04535141
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Olanzapine 5 MG, Placebo
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Sep 17, 2026, 4:09 AM EDT
Withdrawn Not applicable Interventional

Prevention of Unmitigated Chemotherapy-induced Emesis

NCT03996863
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting, Nausea Post Chemotherapy
Interventions
Otoband, Placebo device
Device
Lead sponsor
Otolith Labs
Industry
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)

NCT01054456
View directory record Official record
Conditions
Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC
Interventions
palonesetron
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
Sunrise, Florida • Galesburg, Illinois • Skokie, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant

NCT03097588
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Netupitant, Palonosetron Hydrochloride, Questionnaire Administration
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 11, 2021 · Synced Sep 17, 2026, 4:09 AM EDT
Not listed Phase 4 Interventional

Safety Study of Repeat Doses of SUSTOL in Adults

NCT05434663
View directory record Official record
Conditions
Chemotherapy-Induced Nausea and Vomiting (CINV)
Interventions
SUSTOL
Drug
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Hattiesburg, Mississippi • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Sep 17, 2026, 4:09 AM EDT
Not listed No phase listed Observational

ZeroTolerance Mucositis: Managing Oral and Alimentary Mucositis With High Potency Sucralfate - ProThelial

NCT02016807
View directory record Official record
Conditions
Oral Mucositis, Nausea, Vomiting, Diarrhea
Interventions
ProThelial
Device
Lead sponsor
Ashley Downs Bioscience
Industry
Eligibility
18 Years to 95 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Foster, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Sep 17, 2026, 4:09 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

NCT07169851
View directory record Official record
Conditions
Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
Interventions
LY3537021, Placebo, Standard of Care Antiemetic Therapies, Background Chemotherapy
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Greenbrae, California • Irvine, California • Los Alamitos, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 17, 2026, 4:09 AM EDT